GlassScriptPhysician profile
Charles Thoms Longo
NPI 1073738365
$5,853.53
in general payments reported to CMS, 2019-2025
12 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $1,583 · 2021: $126 · 2022: $550 · 2023: $553 · 2024: $350 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,261.09 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $1,809.23 | 2020-2025 | |
| Abbvie INC. | $335.03 | 2023-2025 | |
| Tela Bio, INC. | $331.85 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Integra Lifesciences Corporation | $205.91 | 2023-2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Mentor Worldwide LLC | $204.16 | 2019-2022 | |
| Sientra, INC. | $200.74 | 2022 | |
| Innovation Technologies INC | $136.88 | 2024 | Irrisept |
| Baudax Bio INC. | $126.26 | 2021 | |
| Kerecis Limited | $89.43 | 2022 | |
| Medtronic USA, INC. | $81.78 | 2020 | |
| Lifenet Health | $71.17 | 2025 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Longo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.